Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates high-resolution imaging of gastrointestinal disorders using tantalum-rich carbon dots, highlighting a safe noninvasive strategy for microlesion detection.
Gastrointestinal (GI) diseases pose significant diagnostic challenges due to nonspecific early symptoms and the difficulty in detecting subtle lesions. Dynamic X-ray imaging and high spatial-resolution computed tomography (CT) provide flexible and powerful tools for the precise diagnosis of diverse GI diseases. However, current clinical X-ray contrast agents still present inherent limitations, as BaSO4 exhibits poor water solubility and iodine-based small molecules encounter issues of iodine allergy, contraindications, and generally low sensitivity. Here we report noninvasive diagnosis of diverse gastrointestinal disorders using tantalum-rich carbon dots (Ta-rCDs) as an X-ray contrast agent. Ta-rCDs are prepared through a simple and scalable high-temperature carbonization process, featuring ultrahigh tantalum content (∼48%), gram-scale yield (3.2 g per batch), ultrasmall hydrodynamic size (∼3 nm), excellent water solubility (>500 mg/mL) and strong X-ray attenuation. In models of small-intestinal stricture and esophageal leakage, Ta-rCDs enable simultaneous dynamic X-ray tracking and high-resolution CT imaging, allowing the visualization of microlesions and demonstrating efficient renal excretion upon entering the peritoneal cavity. Systematic biocompatibility assessments further confirm their good biosafety. Together these findings offered a noninvasive, real-time and high-sensitivity strategy for accurate diagnosis and monitoring of GI diseases.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: